Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

MSLE

Satellos Bioscience Inc

May 01 • 10:37AM ET

7.71

-0.24 -3.02 %

Healthcare • Biotechnology • Canada • Micro • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.73	Insider Own	16.85%	Shs Outstand	20.83M	Perf Week	10.46%
Market Cap	160.60M	Forward P/E	-	EPS next Y	-2.17	Insider Trans	0.00%	Shs Float	17.32M	Perf Month	27.65%
Enterprise Value	132.89M	PEG	-	EPS next Q	-0.49	Inst Own	4.54%	Short Float	0.46%	Perf Quarter	-33.72%
Income	-24.87M	P/S	-	EPS this Y	-15.20%	Inst Trans	5.85%	Short Ratio	0.96	Perf Half Y	16.90%
Sales	0.00M	P/B	4.29	EPS next Y	-10.55%	ROA	-60.18%	Short Interest	0.08M	Perf YTD	31.12%
Book/sh	1.80	P/C	5.80	EPS next 5Y	-6.35%	ROE	-66.36%	52W High	13.39 -42.44%	Perf Year	40.59%
Cash/sh	1.33	P/FCF	-	EPS past 3/5Y	16.48% 36.03%	ROIC	-89.52%	52W Low	4.53 70.24%	Perf 3Y	25.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.50% 9.87%	Perf 5Y	-58.81%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	15.10%	Oper. Margin	-	ATR (14)	0.74	Perf 10Y	7.08%
Dividend Ex-Date	-	Quick Ratio	7.77	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.83	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.77	EPS Q/Q	-49.49%	SMA20	7.19%	Beta	1.65	Target Price	22.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-7.79%	Rel Volume	0.19	Prev Close	7.95
Employees	18	LT Debt/Eq	0.00	Earnings	Mar 27 BMO	SMA200	8.84%	Avg Volume	82.52K	Price	7.71
IPO	Feb 19, 2009	Option/Short	No / Yes	EPS/Sales Surpr.	-32.73% -	Trades		Volume	3,299	Change	-3.02%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-28-26	Initiated	Guggenheim	Buy	$23
Apr-06-26	Initiated	Leerink Partners	Outperform	$20
Mar-11-26	Initiated	Cantor Fitzgerald	Overweight

Apr-09-26 07:00AM	Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference (GlobeNewswire)
Mar-27-26 09:15AM	Satellos Bioscience: Q4 Earnings Snapshot (Associated Press Finance) -10.68%
07:00AM	Satellos Reports 2025 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Mar-10-26 07:00AM	Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference (GlobeNewswire) -18.11%
Feb-24-26 07:00AM	Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference (Business Wire)
07:00AM	Loading…
Feb-18-26 07:00AM	Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy (Business Wire)
Feb-17-26 07:00AM	Satellos to Participate in Upcoming Investor Conferences (Business Wire)
Feb-11-26 08:12AM	Satellos price target raised to $40 from $5 at Oppenheimer (TipRanks) +7.08%
Feb-10-26 07:00AM	Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 (Business Wire)
Feb-09-26 05:00PM	Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)
Feb-06-26 08:30AM	Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States (Business Wire) -5.54%

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX and Leveraging MyoReGenX, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MSLE

Satellos Bioscience Inc

Upgrade your Finviz experience